About: Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models
Creator	Borro, Matteo Gangemi, Sebastiano Greco, Monica Murdaca, Giuseppe Negrini, Simone Puppo, Francesco Tonacci, Alessandro
Source	Medline; PMC
abstract	Introduction: MiRNAs have been shown to play a crucial role among lung cancer, pulmonary fibrosis, tuberculosis (TBC) infection, and bronchial hypersensitivity, thus including chronic obstructive pulmonary disease (COPD) and asthma. The oncogenic effect of several miRNAs has been recently ruled out. In order to act on miRNAs turnover, antagomiRs have been developed. Materials and methods: The systematic review was conducted under the PRISMA guidelines (registration number is: CRD42019134173). The PubMed database was searched between 1 January 2000 and 30 April 2019 under the following search strategy: (((antagomiR) OR (mirna antagonists) OR (mirna antagonist)) AND ((lung[MeSH Terms]) OR (“lung diseases”[MeSH Terms]))). We included original articles, published in English, whereas exclusion criteria included reviews, meta-analyses, single case reports, and studies published in a language other than English. Results and Conclusions: A total of 68 articles matching the inclusion criteria were retrieved. Overall, the use of antagomiR was seen to be efficient in downregulating the specific miRNA they are conceived for. The usefulness of antagomiRs was demonstrated in humans, animal models, and cell lines. To our best knowledge, this is the first article to encompass evidence regarding miRNAs and their respective antagomiRs in the lung, in order to provide readers a comprehensive review upon major lung disorders.
has issue date	2019-08-13(xsd:dateTime)
bibo:doi	10.3390/ijms20163938
bibo:pmid	31412612
has license	cc-by
sha1sum (hex)	3aed588044335032787a5eb91ee61afadcd4a006
schema:url	https://doi.org/10.3390/ijms20163938
resource representing a document's title	Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models
has PubMed Central identifier	PMC6719072
has PubMed identifier	31412612
schema:publication	Int J Mol Sci
resource representing a document's body	covid:3aed588044335032787a5eb91ee61afadcd4a006#body_text
is schema:about of	named entity 'MATCHING' named entity 'LUNG' named entity 'SINGLE CASE REPORTS' named entity 'SYSTEMATIC REVIEW' named entity 'MIRNAS' named entity 'RULED OUT' named entity 'STRATEGY' named entity 'MIRNA' named entity 'ROLE' named entity 'INFECTION' named entity 'ARTICLES' named entity 'SEARCHED' named entity 'METHODS' named entity 'PRISMA' named entity 'ANTAGONIST' named entity 'BEST' named entity 'CELL LINES' named entity 'ANTAGONISTS' named entity 'PUBMED' named entity 'EVIDENCE' named entity 'USE OF' named entity '2019' named entity 'MAJOR' named entity 'ANTAGOMIRS' named entity 'LUNG DISORDERS' named entity 'TERMS' named entity 'TOTAL' named entity 'BRONCHIAL HYPERSENSITIVITY' named entity 'RECENTLY' named entity 'CELLULAR' named entity 'DIFFERENT' named entity 'TUBERCULOSIS' named entity 'COMPREHENSIVE REVIEW' named entity 'LUNG CANCER' named entity 'MATERIALS' named entity 'ANIMAL MODELS' named entity 'OUR' named entity 'EFFECT' named entity 'INCLUSION CRITERIA' named entity 'STUDIES' named entity 'LANGUAGE OTHER THAN ENGLISH' named entity 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE' named entity 'PLAY' named entity 'FOLLOWING' named entity 'JANUARY' named entity 'PUBLISHED' named entity 'EXCLUSION CRITERIA' named entity '2000' named entity 'ASTHMA' named entity 'THEIR' named entity 'TURNOVER' named entity 'ANTAGOMIRS' named entity 'DISEASES IN HUMAN' named entity 'ANIMAL MODELS' named entity 'MOLECULAR' named entity 'SCIENCES' named entity 'NUMBER' named entity 'TO PROVIDE' named entity 'SPECIFIC' named entity 'KNOWLEDGE' named entity 'ACT' named entity 'META-ANALYSES' named entity 'PULMONARY FIBROSIS' named entity 'DATABASE' named entity 'GUIDELINES ' named entity 'RESULTS' named entity 'INCLUDING' named entity 'ORIGINAL' named entity 'CONCEIVED' named entity 'HUMANS' named entity 'CONCLUSIONS' named entity 'ARTICLE' named entity 'OVERALL' named entity 'SEARCH' named entity 'EFFECTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software